Search

Your search keyword '"Lordick, F."' showing total 1,419 results
Start Over Author "Lordick, F."
1,419 results on '"Lordick, F."'

6. The German Network for Personalized Medicine to enhance patient care and translational research

Author

Illert, A. L., Stenzinger, A., Bitzer, M., Horak, P., Gaidzik, V. I., Möller, Y., Beha, J., Öner, Ö., Schmitt, F., Laßmann, S., Ossowski, S., Schaaf, C. P., Hallek, M., Brümmendorf, T. H., Albers, P., Fehm, T., Brossart, P., Glimm, H., Schadendorf, D., Bleckmann, A., Brandts, C. H., Esposito, I., Mack, E., Peters, C., Bokemeyer, C., Fröhling, S., Kindler, T., Algül, H., Heinemann, V., Döhner, H., Bargou, R., Ellenrieder, V., Hillemanns, P., Lordick, F., Hochhaus, A., Beckmann, M. W., Pukrop, T., Trepel, M., Sundmacher, L., Wesselmann, S., Nettekoven, G., Kohlhuber, F., Heinze, O., Budczies, J., Werner, M., Nikolaou, K., Beer, A. J., Tabatabai, G., Weichert, W., Keilholz, U., Boerries, M., Kohlbacher, O., Duyster, J., Thimme, R., Seufferlein, T., Schirmacher, P., and Malek, N. P.

Published
2023
Full Text
View/download PDF

8. Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis

Author

Stolze, T., Franke, S., Haybaeck, J., Moehler, M., Grimminger, P. P., Lang, H., Roth, W., Gockel, I., Kreuser, N., Bläker, H., Wittekind, C., Lordick, F., Vieth, M., Veits, L., Waidmann, O., Lingohr, P., Peitz, U., Schildberg, C., Kruschewski, M., Vassos, N., Goni, E., Bruns, C. J., Ridwelski, K., Wolff, S., Lippert, H., Schumacher, J., Malfertheiner, P., and Venerito, M.

Published
2023
Full Text
View/download PDF

12. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Author

Ducreux, M., Abou-Alfa, G.K., Bekaii-Saab, T., Berlin, J., Cervantes, A., de Baere, T., Eng, C., Galle, P., Gill, S., Gruenberger, T., Haustermans, K., Lamarca, A., Laurent-Puig, P., Llovet, J.M., Lordick, F., Macarulla, T., Mukherji, D., Muro, K., Obermannova, R., O’Connor, J.-M., O’Reilly, E.M., Osterlund, P., Philip, P., Prager, G., Ruiz-Garcia, E., Sangro, B., Seufferlein, T., Tabernero, J., Verslype, C., Wasan, H., and Van Cutsem, E.

Published
2023
Full Text
View/download PDF

23. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Author

Addeo, A., Albiges, L., Ascierto, P.A., Banerjee, S., Barlesi, F., Caldas, C., Cardoso, F., Cervantes, A., Chaberny, I.F., Cherny, N.I., Choueiri, T.K., Chua, M.L.K., Criscitiello, C., Curigliano, G., de Azambuja, E., De Ruysscher, D., de Vries, E., Dent, R., Douillard, J.Y., D’Ugo, D., Dziadziuszko, R., Faivre-Finn, C., Felip, E., Garassino, M., Garrido, P., Girard, N., Glynne-Jones, R., Golfinopoulos, V., Haanen, J., Hamilton, E., Jänne, P.A., Jordan, K., Kanesvaran, R., Kim, S.B., Liebert, U.G., Lordick, F., Machiels, J.P., Michielin, O., Mok, T.S.K., Morgan, G., Obermannova, R., Park, K., Passaro, A., Pentheroudakis, G., Peters, S., Reck, M., Salazar Soler, R., Scotté, F., Senan, S., Sessa, C., Smyth, E., Soo, R., Soria, J.C., Spicer, J., Strasser, F., Tabernero, J., Tan, D.S.W., Trapani, D., Van Cutsem, E., van Halteren, H., van Schil, P.E., Veronesi, G., Yang, J., and Garassino, M.C.

Published
2020
Full Text
View/download PDF

24. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Author

Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., Hofheinz, R.-D., Al-Batran, S.E., Vogel, A., Mueller, L., Lutz, M.P., Lordick, F., Alsina, M., Borchert, K., Greil, R., Eisterer, W., Schad, A., Slotta-Huspenina, J., Van Cutsem, E., and Lorenzen, S.

Published
2020
Full Text
View/download PDF

25. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients with Cancer

Author

Cella, C, Knoedler, M, Hall, M, Arcopinto, M, Bagnardi, V, Gervaso, L, Pellicori, S, Spada, F, Zampino, M, Ravenda, P, Frassoni, S, Passaro, A, Milano, M, Laffi, A, Fazio, N, Lordick, F, Cella C. A., Knoedler M., Hall M., Arcopinto M., Bagnardi V., Gervaso L., Pellicori S., Spada F., Zampino M. G., Ravenda P. S., Frassoni S., Passaro A., Milano M., Laffi A., Fazio N., Lordick F., Cella, C, Knoedler, M, Hall, M, Arcopinto, M, Bagnardi, V, Gervaso, L, Pellicori, S, Spada, F, Zampino, M, Ravenda, P, Frassoni, S, Passaro, A, Milano, M, Laffi, A, Fazio, N, Lordick, F, Cella C. A., Knoedler M., Hall M., Arcopinto M., Bagnardi V., Gervaso L., Pellicori S., Spada F., Zampino M. G., Ravenda P. S., Frassoni S., Passaro A., Milano M., Laffi A., Fazio N., and Lordick F.

Abstract

Importance: The assessment of the risk of venous thromboembolism (VTE) among outpatients with cancer represents an unsolved topic. Current international guidelines recommend primary prophylaxis for patients at intermediate to high risk of VTE, indicated by a Khorana score of 2 or more. A previous prospective study developed the ONKOTEV score, a 4-variable risk assessment model (RAM) consisting of a Khorana score of more than 2, metastatic disease, vascular or lymphatic compression, and previous VTE event. Objective: To validate the ONKOTEV score as a novel RAM to assess the risk of VTE among outpatients with cancer. Design, Setting, and Participants: ONKOTEV-2 is a noninterventional prognostic study conducted in 3 European centers located in Italy, Germany, and the United Kingdom among a prospective cohort of 425 ambulatory patients with a histologically confirmed diagnosis of a solid tumor who were receiving active treatments. The total study duration was 52 months, with an accrual period of 28 months (from May 1, 2015, to September 30, 2017) and an overall follow up-period of 24 months (data were censored September 30, 2019). Statistical analysis was performed in October 2019. Exposures: The ONKOTEV score was calculated for each patient at baseline by collecting clinical, laboratory, and imaging data from tests performed for routine practice. Each patient was then observed to detect any thromboembolic event throughout the study period. Main Outcomes and Measures: The primary outcome of the study was the incidence of VTE, including deep vein thrombosis and pulmonary embolism. Results: A total of 425 patients (242 women [56.9%]; median age, 61 years [range, 20-92 years]) were included in the validation cohort of the study. The cumulative incidences for the risk of developing VTE at 6 months were 2.6% (95% CI, 0.7%-6.9%), 9.1% (95% CI, 5.8%-13.2%), 32.3% (95% CI, 21.0%-44.1%), and 19.3% (95% CI, 2.5%-48.0%), respectively, among 425 patients with an ONKOTEV score of 0

Published
2023

28. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Author

Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., Al-Batran, S.E., Wiechen, K., Dhaene, K., Maurus, D., Gold, M., Huber, C., Krivoshik, A., Arozullah, A., Park, J.W., and Schuler, M.

Published
2019
Full Text
View/download PDF

29. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Author

Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., and Douillard, J -Y

Published
2019
Full Text
View/download PDF

30. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Author

Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Kato, K., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Nakajima, T.E., Shitara, K., Kawakami, H., Narita, Y., Yoshino, T., Van Cutsem, E., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., and Douillard, J -Y

Published
2019
Full Text
View/download PDF

33. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II

Author

Dietz, A., Wichmann, G., Kuhnt, T., Pfreundner, L., Hagen, R., Scheich, M., Kölbl, O., Hautmann, M.G., Strutz, J., Schreiber, F., Bockmühl, U., Schilling, V., Feyer, P., de Wit, M., Maschmeyer, G., Jungehülsing, M., Schroeder, U., Wollenberg, B., Sittel, C., Münter, M., Lenarz, T., Klussmann, J.P., Guntinas-Lichius, O., Rudack, C., Eich, H.T., Foerg, T., Preyer, S., Westhofen, M., Welkoborsky, H.J., Esser, D., Thurnher, D., Remmert, S., Sudhoff, H., Görner, M., Bünzel, J., Budach, V., Held, S., Knödler, M., Lordick, F., Wiegand, S., Vogel, K., Boehm, A., Flentje, M., and Keilholz, U.

Published
2018
Full Text
View/download PDF

44. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

Author

Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, Rossum, P.S.N. van, Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, and Rossum, P.S.N. van

Abstract

Item does not contain fulltext, BACKGROUND: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. METHODS: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). RESULTS: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). CONCLUSION: The OMEC project has resul

Published
2023

45. Dissecting the genetic heterogeneity of gastric cancer

Author

Hess, T., Maj, C., Gehlen, J., Borisov, O., Haas, S. L., Gockel, I., Vieth, M., Piessen, G., Alakus, H., Vashist, Y., Pereira, C., Knapp, M., Schuller, V., Quaas, A., Grabsch, H. I., Trautmann, J., Malecka-Wojciesko, E., Mokrowiecka, A., Speller, J., Mayr, A., Schroder, J., Hillmer, A. M., Heider, D., Lordick, F., Perez-Aisa, A., Campo, R., Espinel, J., Geijo, F., Thomson, C., Bujanda, L., Sopena, F., Lanas, A., Pellise, M., Pauligk, C., Goetze, T. O., Zelck, C., Reingruber, J., Hassanin, E., Elbe, P., Alsabeah, S., Lindblad, M., Nilsson, M., Kreuser, N., Thieme, R., Tavano, F., Pastorino, Roberta, Arzani, D., Persiani, Roberto, Jung, J. -O., Nienhuser, H., Ott, K., Schumann, R. R., Kumpf, O., Burock, S., Arndt, V., Jakubowska, A., Lawniczak, M., Moreno, V., Martin, V., Kogevinas, M., Pollan, M., Dabrowska, J., Salas, A., Cussenot, O., Boland-Auge, A., Daian, D., Deleuze, J. -F., Salvi, E., Teder-Laving, M., Tomasello, G., Ratti, M., Senti, C., De Re, V., Steffan, A., Holscher, A. H., Messerle, K., Bruns, C. J., Sivins, A., Bogdanova, I., Skieceviciene, J., Arstikyte, J., Moehler, M., Lang, H., Grimminger, P. P., Kruschewski, M., Vassos, N., Schildberg, C., Lingohr, P., Ridwelski, K., Lippert, H., Fricker, N., Krawitz, P., Hoffmann, Christian Pieter, Nothen, M. M., Veits, L., Izbicki, J. R., Mostowska, A., Martinon-Torres, F., Cusi, D., Adolfsson, R., Cancel-Tassin, G., Hoblinger, A., Rodermann, E., Ludwig, M., Keller, G., Metspalu, A., Brenner, H., Heller, J., Neef, M., Schepke, M., Dumoulin, F. L., Hamann, L., Cannizzaro, Rino, Ghidini, Maria Candida, Plassmann, D., Geppert, M., Malfertheiner, P., Gehlen, O., Skoczylas, T., Majewski, M., Lubinski, J., Palmieri, O., Boccia, Stefania, Latiano, A., Aragones, N., Schmidt, T., Dinis-Ribeiro, M., Medeiros, R., Al-Batran, S. -E., Leja, M., Kupcinskas, J., Garcia-Gonzalez, M. A., Venerito, M., Schumacher, J., Pastorino R. (ORCID:0000-0001-5013-0733), Persiani R. (ORCID:0000-0002-1537-5097), Hoffmann P., Cannizzaro R., Ghidini M., Boccia S. (ORCID:0000-0002-1864-749X), Hess, T., Maj, C., Gehlen, J., Borisov, O., Haas, S. L., Gockel, I., Vieth, M., Piessen, G., Alakus, H., Vashist, Y., Pereira, C., Knapp, M., Schuller, V., Quaas, A., Grabsch, H. I., Trautmann, J., Malecka-Wojciesko, E., Mokrowiecka, A., Speller, J., Mayr, A., Schroder, J., Hillmer, A. M., Heider, D., Lordick, F., Perez-Aisa, A., Campo, R., Espinel, J., Geijo, F., Thomson, C., Bujanda, L., Sopena, F., Lanas, A., Pellise, M., Pauligk, C., Goetze, T. O., Zelck, C., Reingruber, J., Hassanin, E., Elbe, P., Alsabeah, S., Lindblad, M., Nilsson, M., Kreuser, N., Thieme, R., Tavano, F., Pastorino, Roberta, Arzani, D., Persiani, Roberto, Jung, J. -O., Nienhuser, H., Ott, K., Schumann, R. R., Kumpf, O., Burock, S., Arndt, V., Jakubowska, A., Lawniczak, M., Moreno, V., Martin, V., Kogevinas, M., Pollan, M., Dabrowska, J., Salas, A., Cussenot, O., Boland-Auge, A., Daian, D., Deleuze, J. -F., Salvi, E., Teder-Laving, M., Tomasello, G., Ratti, M., Senti, C., De Re, V., Steffan, A., Holscher, A. H., Messerle, K., Bruns, C. J., Sivins, A., Bogdanova, I., Skieceviciene, J., Arstikyte, J., Moehler, M., Lang, H., Grimminger, P. P., Kruschewski, M., Vassos, N., Schildberg, C., Lingohr, P., Ridwelski, K., Lippert, H., Fricker, N., Krawitz, P., Hoffmann, Christian Pieter, Nothen, M. M., Veits, L., Izbicki, J. R., Mostowska, A., Martinon-Torres, F., Cusi, D., Adolfsson, R., Cancel-Tassin, G., Hoblinger, A., Rodermann, E., Ludwig, M., Keller, G., Metspalu, A., Brenner, H., Heller, J., Neef, M., Schepke, M., Dumoulin, F. L., Hamann, L., Cannizzaro, Rino, Ghidini, Maria Candida, Plassmann, D., Geppert, M., Malfertheiner, P., Gehlen, O., Skoczylas, T., Majewski, M., Lubinski, J., Palmieri, O., Boccia, Stefania, Latiano, A., Aragones, N., Schmidt, T., Dinis-Ribeiro, M., Medeiros, R., Al-Batran, S. -E., Leja, M., Kupcinskas, J., Garcia-Gonzalez, M. A., Venerito, M., Schumacher, J., Pastorino R. (ORCID:0000-0001-5013-0733), Persiani R. (ORCID:0000-0002-1537-5097), Hoffmann P., Cannizzaro R., Ghidini M., and Boccia S. (ORCID:0000-0002-1864-749X)

Abstract

Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture. Methods: We did a meta-analysis of ten European genome-wide association studies (GWAS) of GC and its subtypes. All patients had a histopathologically confirmed diagnosis of gastric adenocarcinoma. For the identification of risk genes among GWAS loci we did a transcriptome-wide association study (TWAS) and expression quantitative trait locus (eQTL) study from gastric corpus and antrum mucosa. To test whether cardia GC and OAC/BO share genetic aetiology we also used a European GWAS sample with OAC/BO. Findings: Our GWAS consisting of 5816 patients and 10,999 controls highlights the genetic heterogeneity of GC according to its subtypes. We newly identified two and replicated five GC risk loci, all of them with subtype-specific association. The gastric transcriptome data consisting of 361 corpus and 342 antrum mucosa samples revealed that an upregulated expression of MUC1, ANKRD50, PTGER4, and PSCA are plausible GC-pathomechanisms at four GWAS loci. At another risk locus, we found that the blood-group 0 exerts protective effects for non-cardia and diffuse GC, while blood-group A increases risk for both GC subtypes. Furthermore, our GWAS on cardia GC and OAC/BO (10,279 patients, 16,527 controls) showed that both cancer entities share genetic aetiology at the polygenic level and identified two new risk loci on the single-marker level. Interpretation: Our findings show that the pathophysiology of GC is genetically heterogenous according to location and histopathology. Moreover, our findings point to common molecular me

Published
2023

46. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona

Author

Van Laethem, J.-L., Carneiro, F., Ducreux, M., Messman, H., Lordick, F., Ilson, D.H., Allum, W.H., Haustermans, K., Lepage, C., Matysiak-Budnik, T., Cats, A., Schmiegel, W., Cervantes, A., Van Cutsem, E., Rougier, Ph., and Seufferlein, Th.

Published
2016
Full Text
View/download PDF

47. Indikationen zur prä- und postoperativen Therapie mit Imatinib bei gastrointestinalen Stromatumoren

Author

Heger, U., Weitz, J., and Lordick, F.

Abstract

Zusammenfassung: Imatinib ist ein gegen KIT- und PDGF- („platelet-derived growth factor“) α-Rezeptor gerichteter Tyrosinkinaseinhibitor mit nachgewiesener Wirksamkeit bei metastasiertem gastrointestinalem Stromatumor (GIST). Bei lokal fortgeschrittenem GIST erwies sich eine primäre Therapie mit Imatinib als durchführbar. Die Ansprechraten lagen bei bis zu 70%. Die Behandlung mit Imatinib alleine ist allerdings nicht kurativ. Das mediane progressionsfreie Überleben liegt bei 2 Jahren. Bei lokalisiertem GIST ist die R0-Resektion das Ziel jeder kurativ intendierten chirurgischen Therapie. Daher empfiehlt sich bei fraglicher R0-Resektablität die neoadjuvante Therapie mit Imatinib, in der Regel für eine Dauer von 4–6 Monaten. Nach R0-Resektion von GIST mit intermediärem und hohem Rezidivrisiko deuten erste Daten darauf hin, dass die Einnahme von Imatinib für mindestens ein Jahr das Rezidivrisiko mindert und die Prognose verbessert. Reife Überlebensdaten aus randomisierten Studien fehlen aber bislang, so dass die adjuvante Therapie mit Imatinib außerhalb klinischer Studien aktuell kein Therapiestandard ist. Der Einschluss von Patienten in laufende klinische Studien ist bei intermediärem und hohem Rezidivrisiko dringend anzuraten.

Published
2024
Full Text
View/download PDF

48. The German Network for Personalized Medicine to enhance patient care and translational research

Author

Illert, A. L., Stenzinger, A., Bitzer, M., Horak, P., Gaidzik, V. I., Möller, Y., Beha, J., Öner, Ö., Schmitt, F., Laßmann, S., Ossowski, S., Schaaf, C. P., Hallek, M., Brümmendorf, T. H., Albers, P., Fehm, T., Brossart, P., Glimm, H., Schadendorf, D., Bleckmann, A., Brandts, C. H., Esposito, I., Mack, E., Peters, C., Bokemeyer, C., Fröhling, S., Kindler, T., Algül, H., Heinemann, V., Döhner, H., Bargou, R., Ellenrieder, V., Hillemanns, P., Lordick, F., Hochhaus, A., Beckmann, M. W., Pukrop, T., Trepel, M., Sundmacher, L., Wesselmann, S., Nettekoven, G., Kohlhuber, F., Heinze, O., Budczies, J., Werner, M., Nikolaou, K., Beer, A. J., Tabatabai, G., Weichert, W., Keilholz, U., Boerries, M., Kohlbacher, O., Duyster, J., Thimme, R., Seufferlein, T., Schirmacher, P., and Malek, N. P.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results